<div id="readability-page-1"><p>In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Context Therapeutics, with a price target of <span id="expert-recommendation-target">$7.00</span>.</p><h3>Easter Sale - 70% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Roy covers the Healthcare sector, focusing on stocks such as CervoMed, Enliven Therapeutics, and Oric Pharmaceuticals. According to TipRanks, Roy has an average return of <span>-7.2%</span> and a 32.22% success rate on recommended stocks. </p> <p>In addition to JonesTrading, Context Therapeutics also received a Buy from Maxim Group’s Jason McCarthy in a report issued on April 2. However, on April 3, TipRanks – xAI reiterated a Hold rating on Context Therapeutics (NASDAQ: CNTX).</p></div>

LABU

CNTX

SBIO

<p>JonesTrading analyst Soumit Roy has maintained a Buy rating on Context Therapeutics (CNTX) with a price target of $7.00. Roy, who focuses on the Healthcare sector, has an average return of -7.2% and a 32.22% success rate on his stock recommendations. Additionally, Maxim Group's Jason McCarthy also issued a Buy rating for CNTX, while TipRanks reiterated a Hold rating on April 3.</p>

Tip Ranks

Direxion S&P Biotech Bull 3X

Context Therapeutics

ALPS Medical Breakthrough

Health Care Select Sector SPDR

iShares US Pharma

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VG Health

VanEck Biotech ETF

SPDR S&P Biotech

Ark Genomic Revolution ETF

JonesTrading Remains a Buy on Context Therapeutics (CNTX)